Though our pre-clinical findings were contained within the KP syngeneic model, the increase in PD-L1 expression in mutant KRAS;STK11 (KL) lung cancer cell lines suggest that our proposed therapeutic strategy may be extended to KL lung cancer subtypes. This evidence concerns the gene CD274 and lung cancer.